Is hypercholesterolemia a risk factor for Alzheimer's disease?

Molecular Neurobiology

Volumn 31, Issue 1-3, 2005, Pages 185-192

  Wood, W Gibson ^a   Igbavboa, Urule ^a   Eckert, Gunter P ^b   Johnson Anuna, Leslie N ^a   Müller, Walter E ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyloid protein; Apolipoprotein E, cholesterol; Lipoproteins; Statins

Indexed keywords

ALZHEIMER DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; HUMAN; HYPERCHOLESTEROLEMIA; PATIENT; RISK FACTOR; SERUM; TISSUE LEVEL;

EID: 24644464155     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:31:1-3:185     Document Type: Conference Paper

References (49)

1. Burns M. and Duff K. (2002) Cholesterol in Alzheimer's disease and tauopathy. Ann. NY Acad. Sci. 977, 367-375.
2. Wood W.G., Eckert G.P., Igbavboa U., and Müller W.E. (2003) Amyloid beta-peptide interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta. 1610, 281-290.
3. Wolozin B. (2004) Cholesterol and the biology of Alzheimer's disease. Neuron 41, 7-10.
4. Saunders A.M., Strittmatter W.J., Schmechel D., et al. (1993) Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472.
5. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
6. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
7. Rockwood K., Kirkland S., Hogan D.B., et al. (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227.
8. Zamrini E., McGwin G., and Roseman J.M. (2004) Association between statin use and Alzheimer's disease. Neuroepidemiology 23, 94-98.
9. Hamelin B.A. and Turgeon J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26-37.
10. Puglielli L., Tanzi R.E., and Kovacs D.M. (2003) Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6, 345-351.
11. Hartmann T. (2001) Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 24, S45-S48.
12. Michikawa M. (2003) The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. Mol. Neurobiol. 27, 1-12.
13. Pappolla M.A., Bryant-Thomas T., Herbert D., et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205.
14. Knittweis J.W. and McMullen W.A. (2000) The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study: to the Editor. Neurology 54, 2356-2358.
15. Kuo Y.-M., Emmerling M.R., Bisgaier C.L., et al. (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711-715.
16. Romas S.N., Tang M.X., Berglund L., and Mayeux R. (1999) ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517-521.
17. Evans R.M., Emsley C.L., Gao S., et al. (2000) Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54, 240-242.
18. Kivipelto M., Helkala E.-L., Laakso M.P., et al. (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. Br. Med. J. 322, 1447-1451.
19. Launer L.J., White L.R., Petrovitch H., Ross G.W., and Curb J.D. (2001) Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57, 1447-1452.
20. Tan Z.S., Seshadri S., Beiser A., et al. (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Int. Med. 163, 1053-1057.
21. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 1119-1122.
22. CDC/NCHS. (2003) National Health and Nutrition Examination Survey. CDC/NCHS, Atlanta, GA.
23. Anon. (2003) Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J. Neurosci. Res. 72, 141-146.
24. Frikke-Schmidt R., Nordestgaard B.G., Agerholm-Larsen B., Schnohr P., and Tybjaerg-Hansen A. (2000) Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J. Lipid Res. 41, 1812-1822.
25. Mason R.P., Shoemaker W.J., Shajenko L., Chambers T.E., and Herbette L.G. (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413-419.
26. Sparks D.L. (1997) Coronary artery disease, hypertension, apoE, and cholesterol: a link to Alzheimer's disease? Ann. NY Acad. Sci. 826, 128-146.
27. Eckert G.P., Cairns N.J., Maras A., Gattaz W.F., and Müller W.E. (2000) Cholesterol modulates the membrane disordering effects of β-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 181-186.
28. Heverin M., Bogdanovic N., Lutjohann D., et al. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45, 186-193.
29. Lutjohann D., Breuer O., Ahlborg G., et al. (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. USA 93, 9799-9804.
30. Lund E.G., Xie C., Kotti T., Turley S.D., Dietschy J.M., and Russell D.W. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22,980-22,988.
31. Cutler R.G., Kelly J., Storie K., et al. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101, 2070-2075.
32. Yasojima K., McGeer E.G., and McGeer P.L. (2001) 3-Hydroxy-3- methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. Neuroreport 12, 2935-2938.
33. Mulder M., Ravid R., Swaab D.F., et al. (1998) Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 12, 198-203.
34. Demeester N., Castro G., Desrumaux C., et al. (2000) Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 41, 963-974.
35. Wollmer M.A., Streffer J.R., Lütjohann D., et al. (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol. Aging. 24, 421-426.
36. Papassotiropoulos A., Lutjohann D., Bagli M., et al. (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27-32.
37. 1-42. J. Biol. Chem. 278, 17,150-17,157.
38. Igbavboa U., Avdulov N.A., Chochina S.V., and Wood W.G. (1997) Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochem. 69, 1661-1667.
39. Hayashi H., Igbavboa U., Hamanaka H., et al. (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13, 383-386.
40. Igbavboa U., Avdulov N.A., Schroeder F., and Wood W.G. (1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem. 66, 1717-1725.
41. Wood W.G., Schroeder F., Hogy L., Rao A.M., and Nemecz G. (1990) Asymmetric distribution of a fluorescent sterol in synaptic plasma membranes: effects of chronic ethanol consumption. Biochim. Biophys. Acta 1025, 243-246.
42. Kirsch C., Eckert G.P., and Müller W.E. (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65, 843-856.
43. Lee S.-J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., and Kosik K.S. (1998) A detergent-insoluble membrane compartment contains amyloid-beta in vivo. Nat. Med. 4, 730-734.
44. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., and Holtzman D.M. (2002) Human and murine apoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305-318.
45. Morishima-Kawashima M. and Ihara Y. (1998) The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15,247-15,253.
46. Yamamoto N., Igbavboa U., Shimada Y., et al. (2004) Accelerated Aβ aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569, 135-139.
47. Werner N., Nickenig G., and Laufs U. (2002) Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97, 105-116.
48. Mcfarlane S.I., Muniyappa R., Francisco R., and Sowers J.R. (2002) Pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87, 1451-1458.
49. Johnson-Anuna N.L., Eckert G.P., Keller J.H., et al. (2005) Chronic adminsrration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 312, 786-793.